In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Future Oncol
; 20(3): 131-143, 2024 Jan.
Article
en En
| MEDLINE
| ID: mdl-37807952
ABSTRACT
Aim:
To compare the effectiveness of in-class transition to all-oral ixazomib-lenalidomide-dexamethasone (IRd) following parenteral bortezomib (V)-based induction versus continued V-based therapy in US oncology clinics. Patients &methods:
Non-transplant eligible patients with newly diagnosed multiple myeloma (MM) receiving in-class transition to IRd (N = 100; US MM-6), or V-based therapy (N = 111; INSIGHT MM).Results:
Following inverse probability of treatment weighting, overall response rate was 73.2% with IRd versus 57.5% with V-based therapy (p < 0.0001). Median duration of treatment was 10.8 versus 5.3 months (p < 0.0001). Overall, 18/24% of patients discontinued IRd/V-based therapy due to adverse events.Conclusion:
IRd after V-based induction was associated with significantly improved overall response rate and duration of treatment than continued V-based combination therapy. Clinical Trial Registration US MM-6 NCT03173092; INSIGHT MM NCT02761187 (ClinicalTrials.gov).Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Mieloma Múltiple
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos